You are here: Home > News & Agenda >


Featured Article: European Rare Blood Disorders Platform (ENROL): kick-off meeting on July 2nd.

The European Rare Blood Disorders Platform (ENROL) conceived in the core of ERN-EuroBloodNet to serve as an umbrella for both new and already existing registries on rare haematological disorders (RHD), has officially started June 1st, 2020. The primary objective of ERNOL will be to map at the EU level demographics, survival rates, diagnosis methods, genetic information, main clinical manifestations and treatments as to obtain epidemiological figures and identify trial cohorts for basic and clinical research. To achieve this, ENROL will promote the development of new RHD registries in countries lacking one or connect and facilitate upgrading of existing RHD registries. Furthermore, targeted actions will be carried out in collaboration with EURORDIS for educating patients and families about the benefits of enrolment in such registries. ENROL is co-funded by the European Commission - Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) under the call for proposals HP-PJ-2019 on Rare disease registries for the European Reference Networks. The aims and main objectives, as well as key points of ENROL, will be presented in the online kick-off meeting in July 2nd, 2020, where ERN-EuroBloodNet members, affiliated partners, and other stakeholders’ contribution will be crucial for ENROL implementation and success.

More information here and registration for the kick-off meeting here.

European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia

FRIDAY, JUNE 26, 2020 9:05 AM EDT

Reblozyl regulates late-stage red blood cell (RBC) maturation to potentially reduce or eliminate the need for regular RBC transfusions Reblozyl is the first and only erythroid maturation agent to be approved in the European Union, representing a new class of therapy



The correct treatment and management of infection by Coronavirus (COVID-19) in patients affected by Rare Hematological Diseases may be challenging given the rapid spread of the pandemia and limited literature so far, especially in some countries.

At this crucial stage, efforts are being devoted by different initiatives for the generation of documents with indications for the clinical care of these patients. Find below some of the documents produced with the participation of EuroBloodNet members, including language and target (health professionals or patients).








Oct 8 th 2019




More news



BONE MARROW FAILURE DISORDERS: From the cell to the cure of the disease

November 13-15, 2020

Paris, France

Tim Brümmendorf, Inderjeet Dokal, Carlo Dufour, Régis Peffault de Latour, Marc H.G.P Raaijmakers, Neal Young

 ABOUT THE CONFERENCE: On behalf of the European School of Haematology and the Severe Aplastic Anaemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), we are very pleased to invite you to this Translational Research Conference on Bone Marrow Failure Disorders (BMF). An outstanding faculty of distinguished global experts will present the most recent advances in the field, from the pathophysiology to the diagnosis and therapy of inherited BMF disorders, idiopathic Aplastic Anaemia and Paroxysmal Nocturnal Haemoglobinuria. MAIN TOPICS:   - Stem cell biology: from stress to failure   - Constitutional marrow failure 1: Fanconi Anaemia    - Constitutional marrow failure 2: Ribosome diseases   - Constitutional marrow failure 3: Telomere biology diseases    - Immune Aplastic Anaemia and PNH 1: Pathophysiology and diagnosis    - Idiopathic Aplastic Anaemia and PNH 2: Differential diagnosis and clonal evolution    - Treatment of immune Aplastic Anaemia    - Treatment of PNH   - Emerging areas and new challenges Deadline for applications: September 3, 2020



Copyright © 2002 - 2020 Enerca

Co-funded by the Health Programme of the European Union.